| About the author: |
Skrypnyk I. M., Maslova H. S., Shcherbak O. V. |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
Results of own research are presented in the article. It was demonstrated, that in patients with ischemic heart disease (IHD) associated with non-alcoholic steatohepatitis (NASH), activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltranspeptidase (GGTP) increased 3.8; 2.6 and 3.2 fold accordingly on the background of atherogenic dyslipidemia. These changes were accompanied by such alterations in nitrous oxide system as increase of total nitric oxide synthase activity 2.3 fold with simultaneous nitrites decrease 1.9 fold in comparison with norm. Combination of rosuvastatin in average therapeutic doses with ursodeoxycholic acid (UDCA) and L-carnitine led to normalization of lipid metabolism indexes with achieving the target level of low-density lipoprotein cholesterol below 1.8 mmol/l in 1 month of therapy. Decrease of total nitric oxide synthase activity 2.3 fold and increase of nitrites 1.9 fold in blood serum were observed in the same time. Thus, additional prescription of UDCA and L-carnitine can be recommended in patients with IHD and associated NASH to optimize hypolipidemic therapy. |
| Tags |
ischemic heart disease, nonalcoholic steatohepatitis, nitric oxide, dyslipidemia |
| Bibliography |
- Balahonova TV, Pogorelova OA, Susekov AV. Vliyanie atorvastatina na funktsionalnoe sostoyanie endoteliya u bolnyih s nasledstvennoy giperholesterinemiey. Kardiologiya. 2002; 42 (1): 15-21.
- Besedina AS. NO-syntazna aktyvnist u patsiientiv z ishemichnoiu khvoroboiu sertsia riznykh vikovykh hrup. Bukovynskyi medychnyi visnyk. 2013; 4 (68): 13-17.
- Gubergrits NB, Klochkov AE, Lukashevich GM, Belyaeva NV, Agibalov AN. «Steatel»: ot nauchnyih faktov k klinicheskoy praktike. Suchasna gastroenterologIya. 2014; 2 (76): 116-119.
- Dolzhenko MN, Bazilevich AYa. Novyie aspektyi primeneniya ursodezoksiholevoy kislotyi: vzglyad kardiologa. Zdorove Ukrainyi. 2015; 2: 56-58.
- Dolzhenko MM. Patsient s ishemicheskoy boleznyu serdtsa i hronicheskim steatogepatitom: kak provodit gipolipidemicheskuyu korrektsiyu?. Ukr. med. chasopis. 2007; 1 (57): 89-92.
- Dolzhenko MN, Bazilevich A.Ya. Osobennosti gipolipidemicheskoy terapii u bolnyih s ishemicheskoy boleznyu serdtsa v sochetanii s nealkogolnyim steatogepatitom. Suchasna gastroenterologIya. 2010; 2 (52): 65-69.
- Dolzhenko MM, Bazylevych AIa, Nosenko NM. Vplyv nealkoholnoi zhyrovoi khvoroby pechinky na perebih ishemichnoi khvoroby sertsia za danymy dvorichnoho sposterezhennia . Ukrainskyi kardiolohichnyi zhurnal. 2012; 2: 67-70.
- Zvyagintseva TD, Gluschenko SV. Nealkogolnyiy steatogepatit i metodyi patogeneticheskoy korrektsii. GastroenterologIya. 2014; 2: 29-32.
- Lapshina LA, Kravchun PG, Titova AYu, Glebova OV. Znachenie opredeleniya nitritov-nitratov kak markerov disfunktsii endoteliya pri serdechno-sosudistoy patologii. Ukr. med. chasopis. 2009; 6 (74): 49-53.
- Oganezova LG. Rozuvastatin – optimalnyiy vyibor dlya profilaktiki i lecheniya ateroskleroza. RMZh. 2013; 19: 964.
- Skrypnyk IM, Maslova HS, Shcherbak OV. Osoblyvosti porushen stanu oksydu azotu u khvorykh na ishemichnu khvorobu sertsia v poiednanni z nealkoholnym steatohepatytom u dynamitsi patohenetychnoho likuvannia. Ukrainskyi terapevtychnyi zhurnal. 2017; 3: 20-25.
- Shcherbak OV. Rol L-karnitynu u pidvyshchenni efektyvnosti likuvannia khvorykh na ishemichnu khvorobu sertsia u poiednanni z nealkoholnym steatohepatytom. Aktualni problemy suchasnoi medytsyny. Visnyk Ukrainskoi medychnoi stomatolohichnoi akademii. 2016; 4: 187-192.
- Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapу (MERCURY) II. Am. Heart J. 2006; 151(5): 975.
- Bhatia LS. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur. Heart J. 2012; 33: 1190-1200.
- Cabezas GR. Efecto del acido ursodesoxicolico combinado con estatinas para el tratamiento de la hipercolesterolemia: ensayo clinico prospective. Rev. Clin. Esp. 2004; 1: 632-635.
- Collhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435): 685-696.
- Hevel JM. Purification of the inducible murine macrophage nitricoxide synthase. J. Biol. Chem. 1991; 34: 22.
- Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016; 65:1109-1123.
- Libby P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 2006; 83 (2): 456-460.
- Lubrano V, Vassale C, Franzoni F. Relation between lipid peroxidation and vascular nitric oxide production in endurance athletes and hypercholosterolemic patients before and during atorvastatin therapy. Eur. Heart J. 2000; 21: 153.
- Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation. 2004; 110 (9): 1061-1068.
|
| Publication of the article |
«World of Medicine and Biology» №4(62), 2017 year, 093-099 pages, index UDK 615.272.4:612.015.33: [616.127 – 005.4 – 06:616.36 – 003.826 - 039] |
| DOI |
10.26724/2079-8334-2017-4-62-93-99 |
